Results 191 to 200 of about 5,441,121 (300)

Weighted prevalence of biochemically verified substance use in healthy adolescents across the USA

Addiction, EarlyView.
Abstract Background and aims Adolescent substance use is a significant public health concern, though the scope of the problem is difficult to ascertain given reliance on self‐reported substance use information. Recent, large cohort studies in adolescents and young adults suggest underreporting of substance use.
Natasha E. Wade, Yajuan Si, Susan F. Tapert, Janosch Linkersdörfer, Krista M. Lisdahl, Hailley R. Moore, Laila Tally, Biplabendu Das, Marilyn A. Huestis, Alexander L. Wallace, Ryan M. Sullivan, Veronica Szpak, Le Zhang, Laura Ziemer, Wesley K. Thompson   +14 more
wiley   +1 more source

Healthcare students' knowledge and attitude toward medical cannabis: a cross-sectional study in southeastern Iran. [PDF]

J Cannabis Res
Dehghan M, Behzadi Fard S, Najmadini A, Azizzadeh Forouzi M, Rabiei Vaziri M, Shahidizandi A.   +5 more
europepmc   +1 more source

Alcohol consumption and cognitive function: A systematic review and dose–response meta‐analysis of 20 cohort studies

Addiction, EarlyView.
Abstract Background and aims Amid ongoing debate on whether low‐to‐moderate alcohol consumption reduces cardiovascular risk, studies examining the association between alcohol consumption and cognitive function have reported inconsistent results. To quantitatively assess this association, we conducted a dose–response meta‐analysis of cohort studies ...
Sooyeun Choi, Youjin Je
wiley   +1 more source

UK Medical Cannabis Registry: A Clinical Outcomes Analysis for Migraine. [PDF]

Brain Behav
Hooper L, Erridge S, Clarke E, McLachlan K, Coomber R, Iqbal A, Rucker JJ, Weatherall MW, Sodergren MH.   +8 more
europepmc   +1 more source

Issues spotlight: Medical cannabis [PDF]

Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, 2018
openaire   +2 more sources

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

Addiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

Adverse events associated with medical cannabis reported within a centralized call center. [PDF]

Front Pharmacol
Illamola SM, Lyu X, Luciana M, Dahmer S, Lehfeldt P, Dikmen S, Kaloustian I, Garretson M, Kingston RL, Leppik I, Sherwin CM, Birnbaum AK.   +11 more
europepmc   +1 more source

Prescribed pharmaceutical alternatives initiative coinciding with reductions in unregulated street opioid use among young people who use drugs: An interrupted time series analysis

Addiction, EarlyView.
Abstract Background and aims In British Columbia, Canada, an initiative was implemented in 2020 to reduce overdose mortality by prescribing pharmaceutical opioids (primarily hydromorphone) as a substitute for the toxic unregulated drug supply. This study estimated changes in the level and trend of unregulated opioid use and non‐prescribed hydromorphone
Erica McAdam, Mohammad Karamouzian, Michael John Milloy, Carmen Verdicchio, Eric C. Sayre, Kanna Hayashi, Thomas Kerr, Kora DeBeck   +7 more
wiley   +1 more source

Perceived Prescription Opioid and Medical Cannabis-Related Stigma Among US Adults With and Physicians Who Treat Chronic Pain. [PDF]

Drug Alcohol Rev
Gutkind S, McGinty EE, Stone EM, Tormohlen KN.   +3 more
europepmc   +1 more source

Authorizing medical cannabis for children [PDF]

Paediatrics & Child Health, 2020
openaire   +3 more sources